Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer

Different immunohistochemical programmed death-ligand 1 (PD-L1) assays and scorings have been reported to yield variable results in triple-negative breast cancer (TNBC). We compared the analytical concordance and reproducibility of four clinically relevant PD-L1 assays assessing immune cell (IC) sco...

Full description

Saved in:

Bibliographic Details
Main Authors:	Aurelia Noske, Daniel-Christoph Wagner, Kristina Schwamborn, Sebastian Foersch, Katja Steiger, Marion Kiechle, Dirk Oettler, Siranush Karapetyan, Alexander Hapfelmeier, Wilfried Roth, Wilko Weichert
Format:	article
Language:	EN
Published:	Elsevier 2021
Subjects:	Immunohistochemistry Programmed death-ligand 1 PD-L1 IC-Score CPS Triple-negative breast cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Online Access:	https://doaj.org/article/6df245d0b4404ea2aae7789f9bb50efa
Tags:	Add Tag No Tags, Be the first to tag this record!

id	oai:doaj.org-article:6df245d0b4404ea2aae7789f9bb50efa
record_format	dspace
spelling	oai:doaj.org-article:6df245d0b4404ea2aae7789f9bb50efa2021-11-12T04:25:47ZInterassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer1532-308010.1016/j.breast.2021.11.003https://doaj.org/article/6df245d0b4404ea2aae7789f9bb50efa2021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S0960977621009851https://doaj.org/toc/1532-3080Different immunohistochemical programmed death-ligand 1 (PD-L1) assays and scorings have been reported to yield variable results in triple-negative breast cancer (TNBC). We compared the analytical concordance and reproducibility of four clinically relevant PD-L1 assays assessing immune cell (IC) score, tumor proportion score (TPS), and combined positive score (CPS) in TNBC. Primary TNBC resection specimens (n = 104) were stained for PD-L1 using VENTANA SP142, VENTANA SP263, DAKO 22C3, and DAKO 28–8. PD-L1 expression was scored according to guidelines on virtual whole slide images by four trained readers.The mean PD-L1 positivity at IC-score ≥1% and CPS ≥1 ranged between 53% and 75% with the highest positivity for SP263 and comparable levels for 22C3, 28–8, and SP142. Inter-assay agreement was good between 28–8 and 22C3 across all scores and cut-offs (kappa 0.68–0.74) and for both assays with SP142 at IC-score ≥1% and CPS ≥1 (kappa 0.61–0.67). The agreement between SP263 and all other assays was substantially lower for all scores. Inter-reader agreement for each assay was good to excellent for IC-score ≥1% (kappa 0.73–0.78) and CPS ≥1 (kappa 0.68–0.74), fair to good for CPS ≥10 (kappa 0.52–0.67) and TPS ≥1% (kappa 0.53–0.72). The percentage of overlapping cases in the positive/negative category was >90% between IC-score ≥1% and CPS ≥1 but below when comparing IC-score ≥1% with CPS ≥10. We demonstrate an overall good inter-reader agreement for all PD-L1 assays in TNBC along with assay specific differences in positivity and concordances, which may aid to select the right test strategy in routine diagnostics.Aurelia NoskeDaniel-Christoph WagnerKristina SchwambornSebastian FoerschKatja SteigerMarion KiechleDirk OettlerSiranush KarapetyanAlexander HapfelmeierWilfried RothWilko WeichertElsevierarticleImmunohistochemistryProgrammed death-ligand 1PD-L1IC-ScoreCPSTriple-negative breast cancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast, Vol 60, Iss , Pp 238-244 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunohistochemistry Programmed death-ligand 1 PD-L1 IC-Score CPS Triple-negative breast cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunohistochemistry Programmed death-ligand 1 PD-L1 IC-Score CPS Triple-negative breast cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Aurelia Noske Daniel-Christoph Wagner Kristina Schwamborn Sebastian Foersch Katja Steiger Marion Kiechle Dirk Oettler Siranush Karapetyan Alexander Hapfelmeier Wilfried Roth Wilko Weichert Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
description	Different immunohistochemical programmed death-ligand 1 (PD-L1) assays and scorings have been reported to yield variable results in triple-negative breast cancer (TNBC). We compared the analytical concordance and reproducibility of four clinically relevant PD-L1 assays assessing immune cell (IC) score, tumor proportion score (TPS), and combined positive score (CPS) in TNBC. Primary TNBC resection specimens (n = 104) were stained for PD-L1 using VENTANA SP142, VENTANA SP263, DAKO 22C3, and DAKO 28–8. PD-L1 expression was scored according to guidelines on virtual whole slide images by four trained readers.The mean PD-L1 positivity at IC-score ≥1% and CPS ≥1 ranged between 53% and 75% with the highest positivity for SP263 and comparable levels for 22C3, 28–8, and SP142. Inter-assay agreement was good between 28–8 and 22C3 across all scores and cut-offs (kappa 0.68–0.74) and for both assays with SP142 at IC-score ≥1% and CPS ≥1 (kappa 0.61–0.67). The agreement between SP263 and all other assays was substantially lower for all scores. Inter-reader agreement for each assay was good to excellent for IC-score ≥1% (kappa 0.73–0.78) and CPS ≥1 (kappa 0.68–0.74), fair to good for CPS ≥10 (kappa 0.52–0.67) and TPS ≥1% (kappa 0.53–0.72). The percentage of overlapping cases in the positive/negative category was >90% between IC-score ≥1% and CPS ≥1 but below when comparing IC-score ≥1% with CPS ≥10. We demonstrate an overall good inter-reader agreement for all PD-L1 assays in TNBC along with assay specific differences in positivity and concordances, which may aid to select the right test strategy in routine diagnostics.
format	article
author	Aurelia Noske Daniel-Christoph Wagner Kristina Schwamborn Sebastian Foersch Katja Steiger Marion Kiechle Dirk Oettler Siranush Karapetyan Alexander Hapfelmeier Wilfried Roth Wilko Weichert
author_facet	Aurelia Noske Daniel-Christoph Wagner Kristina Schwamborn Sebastian Foersch Katja Steiger Marion Kiechle Dirk Oettler Siranush Karapetyan Alexander Hapfelmeier Wilfried Roth Wilko Weichert
author_sort	Aurelia Noske
title	Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
title_short	Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
title_full	Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
title_fullStr	Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
title_full_unstemmed	Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
title_sort	interassay and interobserver comparability study of four programmed death-ligand 1 (pd-l1) immunohistochemistry assays in triple-negative breast cancer
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/6df245d0b4404ea2aae7789f9bb50efa
work_keys_str_mv	AT aurelianoske interassayandinterobservercomparabilitystudyoffourprogrammeddeathligand1pdl1immunohistochemistryassaysintriplenegativebreastcancer AT danielchristophwagner interassayandinterobservercomparabilitystudyoffourprogrammeddeathligand1pdl1immunohistochemistryassaysintriplenegativebreastcancer AT kristinaschwamborn interassayandinterobservercomparabilitystudyoffourprogrammeddeathligand1pdl1immunohistochemistryassaysintriplenegativebreastcancer AT sebastianfoersch interassayandinterobservercomparabilitystudyoffourprogrammeddeathligand1pdl1immunohistochemistryassaysintriplenegativebreastcancer AT katjasteiger interassayandinterobservercomparabilitystudyoffourprogrammeddeathligand1pdl1immunohistochemistryassaysintriplenegativebreastcancer AT marionkiechle interassayandinterobservercomparabilitystudyoffourprogrammeddeathligand1pdl1immunohistochemistryassaysintriplenegativebreastcancer AT dirkoettler interassayandinterobservercomparabilitystudyoffourprogrammeddeathligand1pdl1immunohistochemistryassaysintriplenegativebreastcancer AT siranushkarapetyan interassayandinterobservercomparabilitystudyoffourprogrammeddeathligand1pdl1immunohistochemistryassaysintriplenegativebreastcancer AT alexanderhapfelmeier interassayandinterobservercomparabilitystudyoffourprogrammeddeathligand1pdl1immunohistochemistryassaysintriplenegativebreastcancer AT wilfriedroth interassayandinterobservercomparabilitystudyoffourprogrammeddeathligand1pdl1immunohistochemistryassaysintriplenegativebreastcancer AT wilkoweichert interassayandinterobservercomparabilitystudyoffourprogrammeddeathligand1pdl1immunohistochemistryassaysintriplenegativebreastcancer
_version_	1718431295822888960

Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer

Similar Items